|
業務類別
|
Biotechnology |
|
業務概覽
|
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North Americanrights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved EjectionFraction. |
| 公司地址
| 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517 |
| 電話號碼
| +1 919 855-2100 |
| 傳真號碼
| +1 919 855-2133 |
| 公司網頁
| https://www.tenaxthera.com |
| 員工數量
| 6 |
| Mr. Christopher T. Giordano |
Director, President and Chief Executive Officer |
美元 495.68K |
10/03/2026 |
| Dr. Stuart Rich, M.D. |
Director and Chief Medical Officer |
美元 287.83K |
10/03/2026 |
| Mr. Thomas A. McGauley, C.P.A. |
Interim Chief Financial Officer and Principal Accounting Officer |
-- |
10/03/2026 |
|
|
| Mr. Christopher T. Giordano |
Director, President and Chief Executive Officer |
10/03/2026 |
| Dr. Stuart Rich, M.D. |
Director and Chief Medical Officer |
10/03/2026 |
| Ms. Robyn M Hunter |
Independent Director |
10/03/2026 |
| Dr. Michael Harvey Davidson, M.D. |
Independent Director |
10/03/2026 |
| Dr. June S. Almenoff, F.A.C.P.,M.D.,PhD |
Independent Director |
10/03/2026 |
| Dr. Declan Doogan, M.D. |
Independent Director |
10/03/2026 |
| Mr. Gerald T. Proehl |
Chairman of the Board |
10/03/2026 |
|
|
|
|
